Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064089 | 0.89 | HTR2B (0.39) | HTR2BMAPTSLC6A3ALDH1A1 | |
| SCHEMBL491234 | 0.81 | HPGDS (0.44) | HTR2BMAPTSLC6A3 | |
| Hydrochloric Acid SCHEMBL15717196 | 0.80 | HPGDS (0.43) | HTR2BMAPTSLC6A3 | |
| SCHEMBL3572530 | 0.80 | HTR2B (0.33) | HTR2BMAPTSLC6A3 | |
| SCHEMBL15746407 | 0.79 | PLG (0.36) | HTR2BMAPTALDH1A1 | |
| SCHEMBL15747122 | 0.79 | HTR2B (0.33) | HTR2BMAPTALDH1A1 | |
| SCHEMBL12987011 | 0.76 | ESR2 (0.37) | HTR2BMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL20541351 | 0.75 | MAPT (0.32) | HTR2BMAPTALDH1A1 | |
| SCHEMBL15717924 | 0.74 | BAZ2A (0.44) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL18978992 | 0.71 | AOC3 (0.42) | HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HTR2B 2017/4885MAPT 1330/4885SLC6A3 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.